ATE311192T1 - Verfahren zur behandlung von chronischen geschwüren - Google Patents

Verfahren zur behandlung von chronischen geschwüren

Info

Publication number
ATE311192T1
ATE311192T1 AT01937796T AT01937796T ATE311192T1 AT E311192 T1 ATE311192 T1 AT E311192T1 AT 01937796 T AT01937796 T AT 01937796T AT 01937796 T AT01937796 T AT 01937796T AT E311192 T1 ATE311192 T1 AT E311192T1
Authority
AT
Austria
Prior art keywords
ulcer
matrix
treating chronic
chronic ulcers
oxide inhibitors
Prior art date
Application number
AT01937796T
Other languages
English (en)
Inventor
Anton-Lewis Usala
Original Assignee
Encelle Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encelle Inc filed Critical Encelle Inc
Application granted granted Critical
Publication of ATE311192T1 publication Critical patent/ATE311192T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/18—Materials or treatment for tissue regeneration for hair reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01937796T 2000-05-31 2001-05-30 Verfahren zur behandlung von chronischen geschwüren ATE311192T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20811600P 2000-05-31 2000-05-31
PCT/US2001/017387 WO2001091774A2 (en) 2000-05-31 2001-05-30 Method of treating chronic ulcers

Publications (1)

Publication Number Publication Date
ATE311192T1 true ATE311192T1 (de) 2005-12-15

Family

ID=22773242

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01937796T ATE311192T1 (de) 2000-05-31 2001-05-30 Verfahren zur behandlung von chronischen geschwüren

Country Status (8)

Country Link
US (2) US7700660B2 (de)
EP (1) EP1289537B1 (de)
AT (1) ATE311192T1 (de)
AU (3) AU6349501A (de)
CA (2) CA2410968C (de)
DE (1) DE60115433T2 (de)
NZ (1) NZ523461A (de)
WO (2) WO2001091773A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7828749B2 (en) * 1996-05-17 2010-11-09 Roche Diagnostics Operations, Inc. Blood and interstitial fluid sampling device
EP1610674A4 (de) * 2003-03-13 2008-05-21 Cheryl M Burgess Verfahren zur verabreichung eines materials an einen patienten zur hautverstärkung
JP2005269232A (ja) * 2004-03-18 2005-09-29 Renesas Technology Corp 周波数混合器
CA2568134A1 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
RU2322247C1 (ru) * 2006-06-16 2008-04-20 Нефедов Виктор Иванович Способ лечения язвенных дефектов при синдроме диабетической стопы
WO2009137074A1 (en) * 2008-05-06 2009-11-12 Indigene Pharmaceuticals, Inc. Compositions and methods for treating diabetic ulcers
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
EP2236617A1 (de) * 2009-03-31 2010-10-06 Leukocare Ag Verfahren zur Endsterilisierung von biofunktionalen Zusammensetzungen
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーＳｐｏｔｌｉｇｈｔ Ｔｅｃｈｎｏｌｏｇｙ Ｐａｒｔｎｅｒｓ Ｌｌｃ 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
JP2014532713A (ja) 2011-11-02 2014-12-08 ハルシオン，インコーポレイテッド 創傷処置の方法及び組成物
MX352601B (es) 2011-12-23 2017-11-30 Pioneer Surgical Tech Matriz continua con particulas osteoconductoras dispersadas en ella, método para formarla y método para regenerar hueso con ella.
JP6816887B2 (ja) * 2015-10-20 2021-01-20 国立大学法人 東京医科歯科大学 発毛促進組成物およびその使用
KR102085404B1 (ko) * 2016-08-31 2020-03-05 주식회사 에스엔비아 부분 비만 치료용 조성물 및 이를 포함하는 마이크로니들
JP7082623B2 (ja) 2016-12-21 2022-06-08 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ シスチンを有するパーソナルケア用組成物
EP3558246B1 (de) 2016-12-21 2021-10-20 Unilever IP Holdings B.V. Körperpflegezusammensetzungen mit glutathionvorläufer mit 4-substituierten resorcinolen und aminosäuren
EA201991003A1 (ru) 2016-12-21 2019-12-30 Юнилевер Н.В. Композиции для личной гигиены, содержащие малорастворимые соединения
CN114767562B (zh) 2016-12-21 2024-05-10 联合利华知识产权控股有限公司 具有氨基酸和烟酰胺化合物的局部皮肤增亮添加剂和组合物
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
US11540984B2 (en) 2018-05-23 2023-01-03 Conopco, Inc. Nanoemulsions and a method for making the same
CN113679846B (zh) * 2021-08-31 2023-05-09 佛山市第一人民医院（中山大学附属佛山医院） 一种毛发再生剂及其制备方法和应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198479A (en) 1979-03-30 1980-04-15 Merck & Co., Inc. Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells
US4520821A (en) * 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US5852009A (en) * 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US4868121A (en) 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
NO166836C (no) * 1985-03-14 1991-09-11 Univ California Fremgangsmaate for behandling av et organtransplantat.
EP0213908A3 (de) 1985-08-26 1989-03-22 Hana Biologics, Inc. Transplantierbares Kunstgewebe und Verfahren
US4902295A (en) 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
GB8604497D0 (en) * 1986-02-24 1986-04-03 Connaught Lab Separation of islets of langerhans
FR2600076A1 (fr) 1986-06-12 1987-12-18 Fond Ctre Nal Transfusion Milieu de culture comportant de l'albumine humaine, procede de preparation d'un produit injectable a partir de ce milieu, produit obtenu et son utilisation, composition obtenue
US5079160A (en) 1987-06-08 1992-01-07 Lacy Paul E Method to isolate clusters of cell subtypes from organs
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
DE68915540T2 (de) 1988-03-09 1994-10-13 Terumo Corp Für zellen eindringbares medizinisches material und kunsthaut.
US4950483A (en) 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
EP0363125A3 (de) 1988-10-03 1990-08-16 Hana Biologics Inc. Produkt, enthaltend vermehrungsfähige Bauchspeicheldrüsen-Endokrinezellen, und Verfahren
US4957902A (en) * 1988-12-20 1990-09-18 Board Of Regents, The University Of Texas System Peptide inhibitors of wound contraction
US5059588A (en) * 1989-10-13 1991-10-22 Procyte Corporation, Incorporated Methods and compositions for healing bone using gly his lys: copper
WO1991009119A1 (en) 1989-12-13 1991-06-27 Trancel Corporation Improved alginate microcapsules, methods of making and using same
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US5192312A (en) 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2071137A1 (en) 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
WO1994015589A1 (en) 1992-12-30 1994-07-21 Clover Consolidated, Limited Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5358969A (en) 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
US5246971A (en) 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
US6231881B1 (en) * 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US5834005A (en) 1992-02-24 1998-11-10 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5824331A (en) * 1992-02-24 1998-10-20 Encelle, Inc. Bioartificial devices and cellular matrices therefor
DE69327281T2 (de) 1992-02-24 2000-08-10 Encelle, Inc. Künstliche endokrine vorrichtung
US5830492A (en) 1992-02-24 1998-11-03 Encelle, Inc. Bioartificial devices and cellular matrices therefor
AU3733293A (en) 1992-02-25 1993-09-13 Alteon Inc. Method and agents for promoting wound healing
WO1993024112A1 (en) 1992-05-29 1993-12-09 Vivorx, Incorporated Microencapsulation of cells
CA2140905A1 (en) 1992-07-29 1994-01-30 Keith E. Dionne Use of pouch of implantation of living cells
US5262055A (en) 1992-10-19 1993-11-16 The University Of Utah Implantable and refillable biohybrid artificial pancreas
DE4431598C2 (de) 1993-03-03 1997-03-20 Michael Sittinger Verfahren zum Herstellen eines Implantates aus Zellkulturen
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
RU2208636C2 (ru) 1994-01-13 2003-07-20 Дзе Рогозин Институт Макрогранула с секреторными клетками, способ ее получения и способ лечения заболеваний, вызванных нарушением функционирования секреторных клеток
US5487899A (en) * 1994-01-31 1996-01-30 Jess Clarke & Sons, Inc. Wound healing
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5840059A (en) 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
CA2179341A1 (en) 1996-04-12 1997-10-13 Gregory S. Korbutt Methods for isolating, enriching and increasing the maturation of cells
CA2251129A1 (en) * 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US5972332A (en) 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
AU736784B2 (en) * 1997-06-03 2001-08-02 Celltran Limited New medicaments based on polymers composed of methacrylamide-modified gelatin
EP1041996A4 (de) * 1997-12-22 2003-05-14 Human Genome Sciences Inc Keratinozyten wachstumsfaktor-2 formulierungen
CA2337051C (en) 1998-07-10 2007-04-17 Encelle, Inc. Methods for increasing vascularization and promoting wound healing
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6046160A (en) * 1999-07-22 2000-04-04 Deroyal Industries, Inc. Composition and method for enhancing wound healing
US6491953B1 (en) * 2000-01-07 2002-12-10 Amcol International Corporation Controlled release compositions and method
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins

Also Published As

Publication number Publication date
AU2001263495B2 (en) 2005-06-02
NZ523461A (en) 2004-11-26
AU6349501A (en) 2001-12-11
US20020065222A1 (en) 2002-05-30
DE60115433D1 (de) 2006-01-05
WO2001091773A2 (en) 2001-12-06
CA2410968A1 (en) 2001-12-06
EP1289537A2 (de) 2003-03-12
CA2410965A1 (en) 2001-12-06
US7700660B2 (en) 2010-04-20
AU2001265151A1 (en) 2001-12-11
US6992062B2 (en) 2006-01-31
CA2410968C (en) 2011-03-29
DE60115433T2 (de) 2006-08-03
WO2001091773A3 (en) 2002-05-02
EP1289537B1 (de) 2005-11-30
WO2001091774A2 (en) 2001-12-06
WO2001091774A3 (en) 2002-05-02
US20020077277A1 (en) 2002-06-20
CA2410965C (en) 2010-09-14

Similar Documents

Publication Publication Date Title
DE60115433D1 (de) Verfahren zur behandlung von chronischen geschwüren
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
DE69905938D1 (de) Kombination von duloxetin mit nichtsteroid-entzündungshemmern für die behandlung von schmerz
DE60142839D1 (de) Botulinum Toxin zur Behandlung von akuten Verletzungen der Skelettmuskeln
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
NO994640D0 (no) Hostestillende midler
AU2001263495A1 (en) Method of treating chronic ulcers
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
ATE239467T1 (de) Methode zur behandlung oder verhütung von interstitieller blasenentzundung
DE69822810D1 (de) Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x
DE69911212D1 (de) Anwendung der hemoproteine in der therapie
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
DE60134656D1 (de) Hilfsmittel und methoden zur transdermalen applikation von felodipin
ATE484293T1 (de) Verfahren zur vorbeugung oder behandlung von diabetes
ATE359789T1 (de) Verwendung von 4-pyridylmethyl-phthalazin- derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
WO2003024398A3 (en) Treatment of sepsis with tafi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties